Dinesh Dhumal

Dinesh Dhumal

Auto-generated profile, based on publicly available information

Dinesh Dhumal

Aix Marseille University, CNRS, Center Interdisciplinaire de Nanoscience de Marseille, UMR 7325, “Equipe Labellisée Ligue Contre le Cancer”, Marseille, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
CGChristina Galanakou
Christina Galanakou
DDDinesh Dhumal
Dinesh Dhumal
LPLing Peng
Ling Peng
With the alarming and prevailing antimicrobial resistance (AMR) comes an urgent need for novel biocompatible antimicrobial agents that are not only effective and robust but also do not induce resistance development

27 September 2024 in Science Advances
Verified
Journal Article
Open access
NZNian Zhang
Nian Zhang
DDDinesh Dhumal
Dinesh Dhumal
SKShanny Hsuan Kuo
Shanny Hsuan Kuo
SLShi Qian Lew
Shi Qian Lew
PPPankaj D. Patil
Pankaj D. Patil
LPLing Peng
Ling Peng
The rapid emergence and spread of multidrug-resistant bacterial pathogens require the development of antibacterial agents that are robustly effective while inducing no toxicity or resistance development. In this context, we designed and synthesized amphiphilic dendrimers as antibacterial candidates. We report the promising potent antibacterial activity shown by the amphiphilic dendrimer AD1b , composed of a long hydrophobic alkyl chain and a tertiary amine-terminated poly(amidoamine) dendron, against a panel of Gram-negative bacteria, including multidrug-resistant Escherichia coli and Acinetobacter baumannii. AD1b exhibited effective activity against drug-resistant bacterial infections in vivo. Mechanistic studies revealed that AD1b targeted the membrane phospholipids phosphatidylglycerol (PG) and cardiolipin (CL), leading to the disruption of the bacterial membrane and proton motive force, metabolic disturbance, leakage of cellular components, and, ultimately, cell death. Together, AD1b that specifically interacts with PG/CL in bacterial membranes supports the use of small amphiphilic dendrimers as a promising strategy to target drug-resistant bacterial pathogens and addresses the global antibiotic crisis.

1 February 2017 in Arabian Journal of Chemistry
Verified
Journal Article
Open access
SGSaurabh B. Ganorkar
Saurabh B. Ganorkar
DDDinesh M. Dhumal
Dinesh M. Dhumal
ASAtul A. Shirkhedkar
Atul A. Shirkhedkar
A simple, rapid, sensitive, robust, stability-indicating RP-HPLC-PDA analytical protocol was developed and validated for the analysis of zileuton racemate in bulk and in tablet formulation. Development of method and resolution of degradation products from forced; hydrolytic (acidic, basic, neutral), oxidative, photolytic (acidic, basic, neutral, solid state) and thermal (dry heat) degradation was achieved on a LC – GC Qualisil BDS C18 column (250mm×4.6mm×5μm) by isocratic mode at ambient temperature, employing a mobile phase methanol and (0.2%, v/v) orthophosphoric acid in ratio of (80:20, v/v) at a flow rate of 1.0mLmin−1 and detection at 260nm. ‘Design of Experiments’ (DOE) employing ‘Central Composite Design’ (CCD) and ‘Response Surface Methodology’ (RSM) were applied as an advancement to traditional ‘One Variable at Time’ (OVAT) approach to evaluate the effects of variations in selected factors (methanol content, flow rate, concentration of orthophosphoric acid) as graphical interpretation for robustness and statistical interpretation was achieved with Multiple Linear Regression (MLR) and ANOVA. The method succeeded over the validation parameters: linearity, precision, accuracy, limit of detection and limit of quantitation, and robustness. The method was applied effectively for analysis of in-house zileuton tablets

13 October 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
DDDinesh M. Dhumal
Dinesh M. Dhumal
PKPriya R. Kothari
Priya R. Kothari
RKRahul Kalhapure
Rahul Kalhapure
KAKrishnacharya G. Akamanchi
Krishnacharya G. Akamanchi
Despite the various therapeutic actions displayed by curcumin, its poor aqueous solubility and bioavailability restricts its biological applications. This problem can be addressed by its efficient loading into a nano formulation. The present paper reports the utilization of a new semi-synthetic oleic acid derived bicephalous heterolipid, E1E, as an oil phase in the formulation development of a self-microemulsifying drug delivery system (SMEDDS) of curcumin to enhance its solubility and bioavailability. The solubility of curcumin in E1E was found to be 14 and 2.6-fold greater than oleic acid and ethyl oleate respectively. The SMEDDS developed from E1E (Curcumin-E1E_SMEDDS5e) had high curcumin loading efficiency of 70.52 ± 2.46 mg g−1, and was able to form spontaneous microemulsion on addition to aqueous phase with mean globule diameter of 22.39 ± 0.2 nm and polydispersity index of 0.243 ± 0.010. In vivo oral bioavailability studies in male Wistar rats revealed that the maximum serum concentration (Cmax) and time taken to reach maximum serum concentration (Tmax) were 4.921 ± 0.42 μg mL−1 and 60 min respectively. The absorption of curcumin increased 26-folds via its delivery through Curcumin-E1E_SMEDDS5e. The cytostatic and total growth inhibition concentrations of Curcumin-E1E_SMEDDS5e against HeLa cell line were almost comparable to doxorubicin (GI50 and TGI < 10 μg mL−1) whereas lethal concentration (LC50) was 71.8 μg mL−1. Further, the minimum inhibitory concentrations against E. coli and S. aureus were 48.62 and 97.65 μg mL−1 respectively. These results suggested potent anticancer, antibacterial activity and non-cytotoxicity of developed Curcumin-E1E_SMEDDS5e. The heterolipid, E1E, proved to be an efficient solubility and bioavailability enhancer for curcumin for formulation development of its SMEDDS.

31 July 2018 in Science China Materials
Verified
Journal Article
Closed access
PDF file
LDLing Ding
Ling Ding
ZLZhenbin Lyu
Zhenbin Lyu
DDDinesh Dhumal
Dinesh Dhumal
CKChai-Lin Kao
Chai-Lin Kao
MBMonique Bernard
Monique Bernard
LPLing Peng
Ling Peng

27 June 2025 in Science Advances
Verified
Journal Article
Open access
XLXi Liu
Xi Liu
DDDinesh Dhumal
Dinesh Dhumal
PCPatricia Santofimia Castaño
Patricia Santofimia Castaño
JLJuan Liu
Juan Liu
MCMarion Casanova
Marion Casanova
LPLing Peng
Ling Peng
Cardiotoxicity, especially human ether-a-go-go–related gene (hERG)–related toxicity, is a leading cause of drug failure or market withdrawal. Reducing hERG binding to obviate potential cardiac toxicity is crucial. Nanotechnology has been applied to drug delivery for reducing drug toxicity and improving efficacy, but few studies have addressed hERG-related cardiotoxicity. We report the use of self-assembling dendrimer nanosystems for drug formulation and delivery, which effectively reduced hERG binding and associated toxicity while promoting therapeutic efficacy. Specifically, these dendrimer nanosystems efficiently encapsulated the antimalarial drug chloroquine, the anticancer agent doxorubicin, and the NUPR1 inhibitor ZZW115, all three having high affinity to hERG channels. These nanoformulations showed three- to eightfold reduced hERG binding affinity, which, in animal models, translated to abolished toxicity. These nanodrugs exhibited prolonged circulation, leading to enhanced accumulation at disease sites and improved treatment outcomes. This study highlights the potential of nanotechnology to reduce hERG binding and related toxicity while improving drug efficacy, offering valuable perspectives for drug development.